In mouse models of non-alcoholic steatohepatitis (NASH), overexpression of GDF-15 was shown to mitigate the progression of NASH, and this mitigation was evidenced by reduced expression of inflammatory and fibrotic genes, as well as decreased levels of liver enzymes, liver weight, and liver triglyceride content (49). This evidence concerns the gene GDF15 and metabolic dysfunction-associated steatohepatitis.